Who
James Paul Lang
Director
Company insider
Files Form 4 as: Director, OptimizeRx; Director, Halozyme Therapeutics; Director, BioVie.
In numbers
- Trades disclosed
- 67
- Buys
- 2
- Sells
- 0
- Bought
- $2.5M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 8 Dec 2016
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —34,517 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —34,517 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,500 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —889 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,342 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,342 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —889 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —9,868 at $0.00 | filing |
| 14 Mar 2025filed 19 Mar 2025 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Bought | $2.4M321,408 at $7.60 | filing |
| 20 Dec 2024filed 7 Jan 2025 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,690 at $0.00 | filing |
| 20 Nov 2024filed 7 Jan 2025 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —61,600 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —13,286 at $0.00 | filing |
| 5 Jun 2024filed 11 Jun 2024 | OPRX OptimizeRxoption or derivative · Business Services | SEC FORM 4 Code M | —10,061 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.